Standing in the shadow of two bigger brothers can be an intimidating place, but being the runt of the group risk family isn't proving such a bad thing for the group critical illness (CI) market lately, writes Owain Thomas
Over the last year the group CI market has seen the withdrawal of Aegon (who left the entire group risk market last summer), yet it has also welcomed two arrivals in new-starter Ellipse and insurance giant Aviva. And even more promisingly, according to this month’s annual Swiss Re group watch report, it was the only one of three sectors to see premiums received increase in the last 12 months. So perhaps the opportunity is available for it to grow out of the shadows of the group life and income protection (IP) markets. This mood of greater confidence is certainly reflected in the gr...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes